NITRO-BID
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jan 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
NITRO-BID by Sanofi is clinical pharmacology: the principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Approved for angina pectoris due to coronary artery disease. First approved in 1982.
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NITRO-BID is a nitroglycerin ointment formulation approved in 1982 for treating angina pectoris due to coronary artery disease. It works by relaxing vascular smooth muscle and dilating peripheral arteries and veins, reducing cardiac workload and promoting coronary blood flow. The drug is administered topically as an injectable formulation.
$0.001BPart D
LOE ApproachingDeclining
Product is in end-of-life phase with minimal Part D spending ($1M in 2023), indicating a small and shrinking commercial team focused on maintenance rather than growth.
Mechanism of Action
CLINICAL PHARMACOLOGY: The principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the…
Worked on NITRO-BID at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.